Login / Signup

Idelalisib in relapsed/refractory diffuse large B-cell lymphoma: results from a Nordic Lymphoma Group phase II trial.

Karin FjordénSara EkbergNevzeta KuricKarin E SmedbyIngemar LagerlöfThomas S LarsenJudit M JørgensenPeter de Nully BrownMats Jerkeman
Published in: British journal of haematology (2021)
Keyphrases
  • diffuse large b cell lymphoma
  • epstein barr virus
  • chronic lymphocytic leukemia
  • open label
  • acute lymphoblastic leukemia
  • placebo controlled
  • acute myeloid leukemia
  • clinical trial
  • double blind